Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
P/E ratio for Inhibrx, Inc. (INBX)
P/E ratio as of 2023: -7.42
According to Inhibrx, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.42. At the end of 2022 the company had a P/E ratio of -6.80.
P/E ratio history for Inhibrx, Inc. from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -7.42 |
| 2022 | -6.80 |
| 2021 | -20.30 |
| 2020 | -11.01 |
| 2019 | -14.67 |
| 2018 | -17.93 |
| 2017 | -30.55 |
| 2016 | -91.20 |